Pharma Pulse 9/25/24: Developing AI/ML Models for Clinical Trials, Studies Suggest Spravato Would Benefit Younger People & more

DPHARM 2024: Developing AI/ML Models for Clinical Trials

In an interview with Nico Saraceno at DPHARM 2024, Munther Baara, VP strategy and innovation, EDETEK touches on the features an effective AI/ML model can provide and how they benefit data management in trials.

Studies Suggest Spravato Would Benefit Younger People With Treatment-Resistant Depression

Spravato is a derivative of the anesthetic ketamine.

The Joys of Talking to ChatGPT

Among the ways I find it useful: It helps me cure writer’s block, prepare for meetings in the car and sightsee. Oh, and hang curtains.

MedImpact Launches Holistic, Personalized Condition Management Solution

MedImpact unveiled MedEmpower Fuel^TM, a personalized, integrated, whole health approach to nutrition, weight loss, and chronic condition management. Incorporating a consumer app, coaching, and advanced clinical support, MedEmpower Fuel offers a tiered approach to engaging members with the greatest health challenges and risks to improve care and control costs.

Nicholas Saraceno on LinkedIn

Certainly an interesting #LogiPharmaUS session this morning regarding "How Pharma Can Better Understand Its Carbon Footprint and Reach Sustainability Goals."Alaina Passavant, Kaushik Datta, Chandan Trehan, Jeff Tucker, and Joe McCannon hammered home several points, including the value in finding common ground on KPIs in the space (you can't improve on what you can't measure), the value of carbon offsetting, and much more. Pharmaceutical Commerce Magazine LogiPharma US

Have news you want us to share in Pharma Pulse? Reach out to Social Media Editor Miranda Schmalfuhs